HAGIL (Hamburger Vigil Study), A Randomized Placebo-controlled Double-blind Study With Modafinil For Treatment Of Fatigue In Patients with Multiple Sclerosis
Aug 2011
Predicting a window of therapeutic opportunity in multiple sclerosis
Dec 2010
Is it possible to measure mobility deficits of patients suffering from multiple sclerosis? Evaluation of mobility of patients with MS with motorical dysfunctions by dint of accelerometers.
Dec 2010
Relapses as surrogate marker for later disability in Multiple Sclerosis. Correspondence.
Dec 2010
The natural history of multiple sclerosis, a geographically based study. 10, relapses and long-term disability
Nov 2010
The effect of relapses and time to onset of progression on disability accumulation in Multiple Sclerosis
Nov 2010
Establish tolerance in MS with peptide-coupled, peripheral blood mononuclear cells - an open, singe centre, MRI-controlled, baseline-to-treatment cross-over, phase I trial in relapsing-remitting MS patients (ETIMS)
Nov 2010
Longitudinal changes in T2 lesion volume in multiple sclerosis, possible restricted utility as a clinical trial outcome
Aug 2010
The measurement of disability
Aug 2010
The additional predictive value of Magnetic Resonance Imaging for the prediction of future relapses if relapse history is available
Aug 2010
Predictive factors in placebo and natural history data
Aug 2010
Steps towards an individual step pattern from three-dimensional accelerations
Aug 2010
A mobile accelerator device in a belt buckle to supplement existing outcome measures - ActiBelt
Aug 2010
Comparing Cost-Effectiveness Models for MS Disease-Modifying Agents, Different Inputs and Assumptions Produce Different Conclusions
Aug 2010
Steps towards a miniaturized, robust and autonomous measurement device for the long-term monitoring of the activity of patients - ActiBelt
Aug 2010
